PLURIPOTENT STEM CELLEmergence of New Stem Cell: Induced Pluripotent Stem Cell
Development toward cell therapy, disease Modeling, and drug discovery.
human pluripotent stem cells (hPSCs), which include human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs), have emerged as promising candidates for cell therapy since they have clear target cell differentiation capacity as well as paracrine effects. Advances in the technologies of hiPSC generation without viruses have heightened the expectations for its clinical use.
ENDOTHELIAL CELLBarriers for Developing hiPSC-EC as Cell Therapy
Elimination of Animal-derived Elements
Fully defined, xenogeneic ingredient-free methods.
Universality
High efficiency and standardization of protocol. Reduced production cost and commercialization.
Generation of high purity ECs
We developed unique system to yield highly purified ECs.
Tumorigenicity and Aberrant Differentiation
Highly pure differentiated ECs lack of aberrant tissue or tumor development.
hiPSC-ECClinically Compatible hiPSC-ECs
Differentiation of ECs from hiPSCs via clinically compatible manner.
Human iPSCs and hiPSC-ECs are generated following guidelines established by the FDA/CBER to ensure the safety of the products and expedite the time for clinical transition. This product has conceptual, technological, scientific and clinical novelty.
We have developed a unique system to differentiate hPSCs into highly purified functional ECs for clinical use including:
- hiPSC generation without viruses
- Fully defined, xenogeneic ingredient-free method
- High efficiency and standardization of protocol / Universality
- Generation of high purity ECs
- No Tumorigenicity and Aberrant Differentiation
NEW BLOOD VESSEL FORMATIONRobust Vessel-Forming Activities of hiPSC-ECs
hiPSC-ECs are effective for promoting recovery from ischemia and inducing organ regeneration
We developed a differentiation system to produce hPSC-ECs to improve the efficiency of differentiation and demonstrated a direct vascular-incorporation of hPSC-ECs into blood vessels in animal models.
Favorable effects of hiPSC-ECs on recovery in:
- Hindlimb ischemia in mice
- Blood flow
- Limb loss index
- Vascular Density
Our Mission is to Develop Innovative Cell Therapy for Cardiovascular Disease
Our Target Disease
Peripheral Artery Occlusive Disease (PAOD/PAD)
Critical Limb Ischemia (CLI)
Coronary Artery Occlusive Disease (CAOD/CAD)
Myocardial Infarction (MI)
Diabetic Peripheral Neuropathy (DPN) / Intractable Wound / Pressure Ulcer
© 2021 KARIS BIO INC. ALL RIGHTS RESERVED